Initial antidepressant treatment can paradoxically worsen symptoms in depressed adolescents by undetermined mechanisms. Interestingly, antidepressants modulate GABAA receptors, which mediate paradoxical effects of other therapeutic drugs, particularly in females. Although the neuroanatomic site of action for this paradox is unknown, elevated GABAA receptor signaling in the nucleus accumbens can disrupt motivation. We assessed fluoxetine's effects on motivated behaviors in pubescent female hamsters -anhedonia in the reward investigational preference (RIP) test as well as anxiety in the anxiety-related feeding/exploration conflict (AFEC) test. We also assessed accumbal signaling by RT-PCR and electrophysiology. Fluoxetine initially worsened motivated behaviors at puberty, relative to adulthood. It also failed to improve these behaviors as pubescent hamsters transitioned into adulthood. Low accumbal mRNA levels of multiple GABAA receptor subunits and GABAsynthesizing enzyme, GAD67, assessed by RT-PCR, suggested low GABAergic tone at puberty. Nonetheless, rapid fluoxetine-induced reductions of α5GABAA receptor and BDNF mRNA levels at puberty were consistent with age-related differences in GABAergic responses to fluoxetine and disruption of the motivational state. Whole-cell patch clamping of accumbal slices also suggested low GABAergic tone by the low amplitude of miniature inhibitory postsynaptic currents (mIPSCs) at puberty. It also confirmed age-related differences in GABAergic responses to fluoxetine. Specifically, fluoxetine potentiated mIPSC amplitude and frequency at puberty, but attenuated the amplitude during adulthood. These results implicate GABAergic tone and GABAA receptor plasticity in adverse motivational responses and resistance to fluoxetine during adolescence.
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Introduction
Despite the widespread use of antidepressants to treat depression, their use by adolescents is controversial because initial treatment is reported to paradoxically worsen depression and anxiety symptoms, including suicidality (Jick et al., 2004; Cusin et al., 2007) . Concerns arising from these side effects led the U.S. Food and Drug Administration to warn of increased risk of suicidality with antidepressant treatment of patients under age 25 (Bridge et al., 2007) . In addition, antidepressants exert only modest therapeutic efficacy, particularly during adolescence (Bridge et al., 2007) . In a review of 17 randomized clinical trials, four trials showed modest efficacy of adult and youth treatment with fluoxetine, but not other selective serotonin reuptake inhibitors (SSRIs). In contrast, 13 other trials found the efficacies to be indistinguishable from those of placebos (Mann et al., 2006) . Thus, there is an urgent need to elucidate underpinnings for antidepressant actions on the adolescent brain.
Few studies have assessed emotional responses to continuous antidepressant treatment during adolescence in animal models. West et al. (2010) systemically infused adolescent male rats with paroxetine through surgically implanted cannulae, which worsened depressionrelated behavior. In other studies, however, adolescent male rats administered paroxetine without cannulation (Karanges et al., 2011) , and adolescent male mice administered fluoxetine through cannulae (Oh et al., 2009) did not show elevations in depression-related behavior. Thus, to our knowledge only one previous study has demonstrated a pro-depressant-like effect of continuous antidepressant treatment in adolescent rodents (West et al., 2010) . Two of the studies described above reported anxiogenic effects of antidepressants in adolescent rats or mice (Oh et al., 2009; Karanges et al., 2011) . Although chronic antidepressant treatment is anxiolytic (Rynn et al., 2011) , acute treatment with some SSRIs and tricyclic antidepressants worsens anxiety in adult mammals (Kshama et al., 1990; Spigset, 1999; Liu et al., 2010) . Interestingly, initial treatment of rats with fluoxetine induced greater Progress in Neuro-Psychopharmacology & Biological Psychiatry 69 (2016) 19-30 
